Low-dose drugs are trending in the field of chronic diseases. This is because their use in combination with other drugs can be more effective than using a single-agent drug when used to produce fixed-dose combinations or prescribed in combination with other drugs, while reducing the safety risk, compared to high-dose products.

Already, three low-dose drug formulations have received reimbursement this month.

According to industry sources on the 17th, Sam Chun Dang Pharm’s ARB-class hypertension drug ‘Mirtel Tab 20mg,’ which contains telmisartan 20mg was listed for reimbursement at KRW 284 as of the 1st of this month.

Until now, the only telmisartan 20mg available in the m